524 related articles for article (PubMed ID: 15756643)
21. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
22. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
Cecconi V; Moro M; Del Mare S; Sidney J; Bachi A; Longhi R; Sette A; Protti MP; Dellabona P; Casorati G
Eur J Immunol; 2010 Jun; 40(6):1603-16. PubMed ID: 20306469
[TBL] [Abstract][Full Text] [Related]
23. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V; Chapiro J; Stroobant V; Ma W; Lurquin C; Lethé B; van Baren N; Van den Eynde BJ; Boon T; Coulie PG
Cancer Res; 2011 Feb; 71(4):1253-62. PubMed ID: 21216894
[TBL] [Abstract][Full Text] [Related]
24. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
[TBL] [Abstract][Full Text] [Related]
25. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
26. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
27. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
30. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
31. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
[TBL] [Abstract][Full Text] [Related]
32. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
33. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
34. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
35. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
[TBL] [Abstract][Full Text] [Related]
36. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
37. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
38. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Lonchay C; van der Bruggen P; Connerotte T; Hanagiri T; Coulie P; Colau D; Lucas S; Van Pel A; Thielemans K; van Baren N; Boon T
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14631-8. PubMed ID: 15452345
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
Zhang Y; Sun Z; Nicolay H; Meyer RG; Renkvist N; Stroobant V; Corthals J; Carrasco J; Eggermont AM; Marchand M; Thielemans K; Wölfel T; Boon T; van der Bruggen P
J Immunol; 2005 Feb; 174(4):2404-11. PubMed ID: 15699177
[TBL] [Abstract][Full Text] [Related]
40. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
